WO2006049300A1 - 血小板血栓症又は臓器障害の検出方法 - Google Patents
血小板血栓症又は臓器障害の検出方法 Download PDFInfo
- Publication number
- WO2006049300A1 WO2006049300A1 PCT/JP2005/020451 JP2005020451W WO2006049300A1 WO 2006049300 A1 WO2006049300 A1 WO 2006049300A1 JP 2005020451 W JP2005020451 W JP 2005020451W WO 2006049300 A1 WO2006049300 A1 WO 2006049300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- degrading enzyme
- vwf
- elastase
- factor
- thrombin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/966—Elastase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/968—Plasmin, i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- the present invention relates to a method for detecting platelet thrombosis or organ damage, in particular, disseminated intravascular coagulation 3 ⁇ 4E ⁇ (Disseminated
- DI intravascular Coagulation
- the von Willebrand factor von in a biological sample eg, blood
- a subject particularly DIC or SIRS patient
- Willebrand factor (vWF) and / or its degradation factors to detect platelet thromboembolism or organ damage such as detection or prediction of the degree of platelet thrombus formation, prediction of the onset of thrombosis or organ damage (i.e. Assessment of the risk of onset), determination of the presence or absence of thrombosis or organ damage, prediction of prognosis of thrombosis or organ damage, monitoring, determination of therapy, etc.
- DIC associated with sepsis activates cytostatic inca and neutrophils such as tumor necrosis factor (TNF- ⁇ ) and interleukin (IL-1) produced from monocytes (macrophages).
- TNF- ⁇ tumor necrosis factor
- IL-1 interleukin
- monocytes themselves and vascular endothelial cells are activated, and tissue factors are expressed on the cell surface, so that microthrombi are formed.
- Microthrombus formation further exacerbates microcirculatory disturbances and causes multiple organ failure (MOF).
- MOF multiple organ failure
- Non-patent Documents 1 and 2 In respiratory distress syndrome, platelets collect in the pulmonary circulation and cause pulmonary artery occlusion. SIRS does not cause an inflammatory reaction due to an increase in the amount of site force in response to a specific antigen, but without specific targets, an immune response is activated nonspecifically in response to an invasion to a living body. It is a group of diseases that cause severe MOF due to in-control of in-production (Non-patent Documents 1 and 2).
- SIRS is classified as non-infectious SIRS and Sepsis, with the former occurring in shock, trauma, burns, or acute knee inflammation, and the latter in the bacteremia of various pathogens and other serious illnesses. Occurs with staining. SIRS is a bioimmune response to pathogen invasion, tissue damage, anoxia, etc., and is a non-specific systemic acute inflammatory response triggered by various endogenous mediators regardless of the type of invasion. Severe organ failure associated with SIRS can be caused by tissue ischemia or inflammation at an early stage.
- SIRS organ dysfunction syndrome
- the levels of inflammatory sites such as TNF_a, IL-1 (interleukin-l), and IL-6 (interleukin_6) in blood are high. This is thought to be a force that causes the activation of the sphere and the enhancement of the blood coagulation reaction.
- Vascular endothelium When activation of neutrophils occurs beyond the cytoprotective action that the cell is doing, neutrophil elastase catecholin G causes proteases of vascular endothelial cells. As a result, microcirculation disturbances and microthrombosis occur. Activated neutrophils accumulate not only in the inflamed area, but also in remote organs such as the lungs and liver (low perfusion pressure and leukocytes tend to adhere).
- Neutrophil elastase (e l as t ase) has a molecular weight of approximately 30,000 neutral protease present in ⁇ 's Lumpur granules.
- Neutrophil elastase digests and degrades phagocytic bacteria and foreign bodies in neutrophils in the physiological state, and elastin, collagen (type III, type IV), fibronectin, and immunoglobulin outside neutrophils. Decomposes blood coagulation factor XIII and regulates tissue biosynthesis.
- Neutrophil elastase in pathological conditions, is a component of the body, such as elastic fibers, proteodalycan, collagen fibers, antithrombin III, a plasmin inhibitor.
- Neutrophil elastase activity Inactivates antithrombin m by acting on the heparin-binding site of antithrombin m, and causes die.
- Neutrophil elastase is a protease inhibitor (a-protease) in the blood.
- AT is an active oxygen released from neutrophils, myelin peroxidase, ratatov
- neutrophil elastase As a result of being oxidized by erin, neutrophil elastase is not inactivated and is considered to damage tissues. Neutrophil elastase has low substrate specificity, so if it is released excessively, or if an inhibitor such as a-AT is deficient, it also degrades biological components, causing neutrophil elastase to damage its own tissue. May cause. Intensely damaged blood vessels Endothelial cells are detached, and platelets adhere and aggregate at the detached site, forming a thrombus.
- vWF is required for the adhesion of this platelet, and this is triggered to form a thrombus after a series of platelet activation processes such as platelet aggregation and intracellular granule release, and hemostasis is performed.
- vWF is secreted into the blood from the vascular endothelium as a macromolecule having a molecular weight of 20, OOOkDa or more, where it is cleaved by the meta-protease vWF-degrading enzyme and circulates in the blood as a multimer of 50 0-20, OOOkDa.
- vWF changes and takes an extended structure.
- vWF-degrading enzymes Unusually large vWF molecules exist in the blood and bind to platelets more effectively, thereby causing platelet aggregation in the blood vessel. It is believed to promote and form thrombus in the microcirculation.
- platelet-based thrombus formation is indispensable for the physiological hemostasis mechanism, but platelets fuse and fibrin form thrombus formation due to the activity of coagulation factors (factor VII, factor II, etc.).
- Non-Patent Document 1 Bone RC, “Critica ICare Medicine” (USA), 1 996, 24, p. 1 125— 1 128
- Non-Patent Document 2 Davies MG. Et al., “Britishjoumal of Surgery” (UK), 1997, 84 ⁇ , p. 920-935 Disclosure
- an object of the present invention is to provide a method for detecting platelet thrombosis or organ damage in a subject (particularly a DIC or SIRS patient), and the detection kit.
- the object is to analyze platelet thrombosis or organ damage in a patient with disseminated intravascular coagulation or systemic inflammatory response syndrome, which analyzes von Willebrand factor-degrading enzyme and Z or its degradation factor according to the present invention. It can be solved by a detection method.
- the degradation factor is a protease selected from the group consisting of elastase, plasmin, and thrombin (more preferably elastase).
- elastase plasmin
- thrombin more preferably elastase.
- Analysis of von Willebrand factor-degrading enzyme is performed by immunological method.
- a pharmaceutical composition comprising as an active ingredient an antagonist or inhibitor, an agonist or an activity regulator for a protease selected from the group consisting of elastase, plasmin, and thrombin. After administration, the analysis is performed.
- the present invention also provides an antibody or fragment thereof that specifically binds to von Willebrand factor-degrading enzyme, and an antibody or fragment thereof that specifically binds to the degradation factor of Z or von Willebrand factor-degrading enzyme.
- the present invention relates to a kit for detecting platelet thrombosis or organ damage in patients with disseminated intravascular coagulation syndrome or systemic inflammatory reaction syndrome.
- kit of the present invention further comprises an antibody or fragment thereof that specifically binds to a vWF-degrading enzyme cleaved by a protease selected from the group consisting of elastase, plasmin, and thrombin.
- analysis includes “detection” for determining the presence or absence of an analyte (for example, vWF), and quantitatively or semi-quantitatively determining the amount or activity of the analyte. You “Measurement” is included.
- the present invention develops as a basic disease such as a subject such as a DIC or SIRS patient, more specifically, urinary tract infection with high elastase, metastatic lung cancer, and Z or acute myeloid leukemia. It enables detection of platelet thrombosis or organ damage in DIC and SIRS patients, and its clinical value is very high. According to the present invention, it is possible to detect platelet thrombosis or organ damage excellent in convenience, rapidity, and specificity.
- FIG. 1 is a drawing showing the results of electrophoresis of a recombinant vWF-degrading enzyme antigen treated with elastase.
- FIG. 2 is a drawing showing the results of electrophoresis of recombinant vWF-degrading enzyme antigen treated with plasmin or thrombin.
- FIG. 3 is a graph showing the correlation between vWF-degrading enzyme and elastase.
- FIG. 4 is a graph showing the distribution of vWF-degrading enzyme antigen levels in each patient group divided by elastase level.
- the amount (concentration) or enzyme activity of vWF-degrading enzyme and / or its degradation factor is quantified and compared with the amount (concentration) or enzyme activity of vWF-degrading enzyme and / or its degradation factor in healthy individuals. This makes it possible to detect (diagnose) thrombosis or organ damage.
- thrombosis or organ damage for example, detection or prediction of the degree of platelet thrombus formation, prediction of the onset of thrombosis or organ damage (that is, evaluation of the risk of onset), thrombosis It also includes determination of the presence or absence of organ damage, prediction of prognosis of thrombosis or organ damage, monitoring, and determination of treatment methods.
- vWF degrading enzyme refers to tyrosine (842) and methionine (843) present in the A2 domain of von Willebrand factor (vWF). Is a meta-oral protease also referred to as ADAMTS 13.
- a decrease in the concentration of vWF-degrading enzyme can be used as an index as compared with a healthy person.
- DIC and SIRS patients with high levels of elastase have a statistically higher concentration of vWF-degrading enzyme contained in body fluid samples than healthy individuals.
- Scientifically significantly decreased (50% or less).
- the risk of developing thrombosis or organ damage is high, and furthermore, the prognostic status of thrombosis or organ damage can be determined to be poor.
- the concentration of vWF-degrading enzyme is within the normal range, it can be determined that the degree of platelet clot formation is low, and that the risk of developing thrombosis or organ damage is low. Furthermore, it can be determined that the prognostic state of thrombosis or organ damage is good.
- Subjects (subjects) to which the method of the present invention can be applied detect the degree of platelet thrombus formation, or develop thrombosis or organ damage (for example, renal damage or liver damage, preferably renal damage) As long as it is a subject requiring a prognostic prediction, for example, DIC or SIRS patients, preferably DIC or SIR S patients with high elastase, eg leukemia (eg acute myeloid Leukemia), infectious diseases (eg, urinary tract infections), or cancer (metastatic lung cancer).
- DIC or SIRS patients preferably DIC or SIR S patients with high elastase, eg leukemia (eg acute myeloid Leukemia), infectious diseases (eg, urinary tract infections), or cancer (metastatic lung cancer).
- thrombosis blood is solidified in blood vessels, and blood vessels are narrowed or completely blocked by blood clots adhering to the blood vessel wall, resulting in blood flow stagnation and damage to tissues and organs.
- platelets in the blood collect at the wound and stop bleeding.
- fibrin fibrin in the blood
- fibrin aggregates to form a thrombus
- completely hemostasis occurs, blood vessel wall cells grow, and blood vessels are repaired.
- a component that dissolves thrombus (fibrin) works, and blood flow is restored. This fibrinolysis does not work properly, and blood clots Thrombosis is what prevents or completely blocks the flow of blood.
- thrombosis thrombosis thrombosis thrombosis thrombosis .
- cerebral embolism cerebral embolism
- transient cerebral ischemic attack in the brain pulmonary thromboembolism in the lung
- angina pectoris myocardial infarction
- intra-atrial thrombus in the heart
- mesenteric thrombus and deep vein thrombosis such as economy syndrome
- the detection is performed by collecting specimens from healthy subjects and subjects (for example, patients with DIC or SIRS), measuring the respective vWF-degrading enzyme concentrations, and comparing the measured values.
- the detection and / or prediction in the subject can be performed only by analyzing vWF-degrading enzyme with respect to the subject to be predicted. .
- the normal value range or the threshold for determination is expected to change depending on various conditions such as the underlying disease, sex, age, etc. Those skilled in the art appropriately select an appropriate population corresponding to the subject. It is possible to determine the normal value range or threshold for judgment by performing statistical processing on the data obtained from the population.
- an immunological technique using an anti-vWF-degrading enzyme antibody or a fragment thereof for example, an enzyme immunoassay, a latex agglutination immunoassay, chemiluminescence immunity
- Measurement method fluorescent antibody method, radioimmunoassay method, immunoprecipitation method, immunohistochemical staining, Western plot, etc.
- biochemical method eg, enzymological measurement method
- molecular biological to measure mRNA level You can list techniques
- the anti-vWF-degrading enzyme antibody or fragment thereof conforms to a known method, for example, the method described in WO 2004Z029242 pamphlet.
- Various immunological measurements for example, It can be carried out according to the method described in WO 2004/029242.
- an immunological method is preferred because of its sensitivity and simplicity.
- the immunological method is a method in which an antibody against vWF-degrading enzyme is used to analyze vWF-degrading enzyme by, for example, ELISA method, latex method, or immunochromatography method.
- immunological methods include competitive methods that label vWF-degrading enzymes, sandwich methods that label antibodies, latex beads methods that observe aggregation of antibody-coated beads, or binding to colored particles such as colloidal gold.
- any method using an antibody against vWF-degrading enzyme is included in the preferred embodiment of the present invention.
- the antibody may be a monoclonal antibody or a polyclonal antibody.
- Antibody fragments such as Fab, Fab ′, F (ab ′) 2, or Fv can also be used.
- the test sample is preferably blood in plasma form, for example.
- body fluids such as bone marrow fluid or saliva can also be used.
- the plasma is preferably citrate plasma or heparin plasma.
- the degradation factor of the vWF-degrading enzyme can be analyzed together with the analysis of the vWF-degrading enzyme or independently of the analysis of the vWF-degrading enzyme.
- the degradation factor for example, at least one of proteases selected from the group consisting of elastase, plasmin, and thrombin can be analyzed.
- the present inventor found that the vWF-degrading enzyme is degraded by elastase, plasmin, or thrombin, and the degradation mode differs depending on elastase, plasmin, or thrombin. I found out. Therefore, the decrease in vWF-degrading enzyme is due to vWF-degrading enzyme by elastase, plasmin, or thrombin.
- platelet thrombosis or organ damage can be detected by analyzing either vWF-degrading enzyme or its degrading factor.
- the degrading factor That is, more accurate detection or prediction can be performed by analyzing protease.
- the change in the protease concentration is used as an index as compared with a healthy person. You can.
- the protease concentration can be measured by various known methods, for example, by the following method.
- Elastase is present in blood with more than 90% bound to ⁇ % antitrypsin.
- This complex can be measured by the ELIS method using a monoclonal antibody.
- thrombin produced in blood cannot be measured directly because it is rapidly neutralized by various factors.
- TAT thrombin and antithrombin
- plasmin Since plasmin disappears from the blood as rapidly as thrombin, it cannot be measured directly. It can be measured as a complex of plasmin and 2 antiplasmin (PIC).
- TAT and PIC complexes are measured by ELISA or latex agglutination using monoclonal or polyclonal antibodies.
- the state of the patient (for example, evaluation of the degree of platelet thrombus formation, or the onset or prognosis of thrombosis or organ damage) is determined. It can also be used for monitoring.
- the pharmaceutical composition is not particularly limited.
- the pharmaceutical composition contains an antagonist or inhibitor for vWF-degrading enzyme or an agonist or activity regulator as an active ingredient, or elastase, plasmin.
- a pharmaceutical composition containing, as an active ingredient, an antagonist or inhibitor, an agonist or an activity regulator for a protease selected from the group consisting of thrombin.
- the present inventor controlled the generation of platelet thrombus and fibrin thrombus.
- elastase degraded vWF degrading enzyme. It is thought that platelet thrombus is formed, and then fibrin is deposited to form fibrin thrombus, and secreted plasmin and thrombin break down vWF-degrading enzyme. For example, it is possible to determine the disease state more accurately by grasping which protease is responsible for the change factor of the vWF-degrading enzyme amount.
- elastase is particularly preferred as a diagnostic index because it has the highest degradation activity of vWF-degrading enzyme and is involved in the early stage.
- the kit of the present invention comprises at least an anti-vWF-degrading enzyme antibody or fragment thereof and an antibody or fragment thereof that specifically binds to a degradation factor of Z or vWF-degrading enzyme, and two or more different anti-vWF-degrading enzyme antibodies, and / or Or it is preferable to include two or more different anti-degradation factor antibodies.
- the kit of the present invention may further contain an antibody or a fragment thereof that specifically binds to a vWF-degrading enzyme cleaved by a protease selected from the group consisting of elastase, plasmin, and thrombin, if desired.
- the kit of the present invention can be used for carrying out the method of the present invention.
- the anti-vWF-degrading enzyme antibody or anti-degrading factor antibody contained in the kit of the present invention can be either a monoclonal antibody or a polyclonal antibody. If two or more different anti-vWF-degrading enzyme antibodies or two or more different anti-degrading factor antibodies are included, either one (second antibody) can be used as a labeled antibody, or labeled. Instead of this, the labeled antibody in which the label is bound to the antibody against the second antibody is further added to the kit.
- vWF-degrading enzyme 1.5 xg is dissolved in Tris buffer / saline solution, and elastase is added to this to a final concentration of 20 nmol / L or 140 nmol / L.
- elastase is added to this to a final concentration of 20 nmol / L or 140 nmol / L.
- 0.5 / ig equivalent of vWF-degrading enzyme was collected. This was separated by non-reducing SDS electrophoresis (5-20% gel) and then transferred to a PVDF (polyvinylidene difluoride) membrane by Western blotting.
- Commercially available blocking agent After blocking at room temperature for 30 minutes with Block Ace (Dainippon Pharmaceutical), the plate was washed with Tris buffer.
- Each lane in FIG. 1 is as follows:
- Lane 1 Calories without elastase
- Lane 2 Reaction at 37 ° C for 15 minutes after addition of 20 nmol ZL elastase
- Lane 3 Reaction at 37 degrees for 15 minutes after adding 140 nmol / L elastase
- Lane 5 1 hour reaction at 37 degrees after addition of 20 nmol / L elastase
- Example 2 Degradation of recombinant vWF-degrading enzyme antigen with plasmin or thrombin
- Recombinant vWF-degrading enzyme 1.5 xg was dissolved in Tris buffer / saline solution, and plasminogen (final concentration 1 ⁇ mol) was added.
- plasminogen final concentration 1 ⁇ mol
- tPA tissue plasminogen activator
- tPA tissue plasminogen activator
- Each lane in FIG. 2 is as follows:
- Lane 1 0.2 nmolZL _tPA added, reaction at 37 degrees for 15 minutes
- Lane 8 Reaction for 1 hour at 37 degrees after addition of 20mmolZL thrombin
- vWF-degrading enzyme antigen level and elastase level were measured using plasma from healthy subjects, DIC patients, and SIRS patients as test samples.
- the amount of vWF-degrading enzyme antigen was measured using a commercial kit (vWF-degrading enzyme ELISA kit; Mitsubishi Chemical Jatron).
- the amount of elastase can be determined by the sales kit (PMN Elastase / a 1-PI
- FIG. 3 The results are shown in FIG. 3 and FIG.
- “NS” means no significant difference.
- neutrophil activation and blood coagulation reaction are promoted by site force-in such as TNF ⁇ , and neutrophil elastase is vascularized by a protease such as cathebsin G.
- site force-in such as TNF ⁇
- neutrophil elastase is vascularized by a protease such as cathebsin G.
- elastase released into the blood to repair damaged tissue actively degrades vWF-degrading enzymes to promote platelet thrombus formation.
- the present invention can be applied to the detection of platelet thrombosis or organ damage in a subject (for example, DIC or SIRS patient).
- DIC is caused by the activation of the coagulation system or the decreased state of coagulation control factors under various basic diseases, and microthrombus occurs frequently in small blood vessels throughout the body. While this causes intravascular occlusion, the depletion of the thrombus formation is due to the consumption of platelets and coagulation fibrinolytic factors. It is a pathological condition in which blood disorders overlap, and severe bleeding tendency and organ damage are observed. Therefore, it is extremely important to detect microthrombus formation early and perform early treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006542468A JP4875495B2 (ja) | 2004-11-08 | 2005-11-08 | 血小板血栓症又は臓器障害の検出方法 |
EP05803016A EP1816211A4 (en) | 2004-11-08 | 2005-11-08 | METHOD OF DETECTING THROMBOSIS OF BLOOD PLAQUETTES OR DEGASTS TO AN ORGAN |
US11/718,853 US7923255B2 (en) | 2004-11-08 | 2005-11-08 | Method of detecting platelet thrombosis or organ failure |
CA002586848A CA2586848A1 (en) | 2004-11-08 | 2005-11-08 | Method of detecting platelet thrombosis or organ injury |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-323770 | 2004-11-08 | ||
JP2004323770 | 2004-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049300A1 true WO2006049300A1 (ja) | 2006-05-11 |
Family
ID=36319296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020451 WO2006049300A1 (ja) | 2004-11-08 | 2005-11-08 | 血小板血栓症又は臓器障害の検出方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7923255B2 (ja) |
EP (2) | EP1816211A4 (ja) |
JP (1) | JP4875495B2 (ja) |
CN (2) | CN102121939A (ja) |
CA (1) | CA2586848A1 (ja) |
ES (1) | ES2399607T3 (ja) |
WO (1) | WO2006049300A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007088849A1 (ja) | 2006-01-31 | 2007-08-09 | Mitsubishi Kagaku Iatron, Inc. | 播種性血管内凝固症候群の病態把握方法 |
WO2007094394A1 (ja) | 2006-02-16 | 2007-08-23 | Mitsubishi Kagaku Iatron, Inc. | 意識障害患者における病態の検出方法及び検出用キット |
JP2008061622A (ja) * | 2006-09-11 | 2008-03-21 | Mitsubishi Kagaku Iatron Inc | 造血幹細胞移植療法の施行患者の病態把握方法 |
JP2008216137A (ja) * | 2007-03-06 | 2008-09-18 | Mitsubishi Kagaku Iatron Inc | 糖尿病性腎症患者の病態把握方法 |
EP3988938A1 (en) | 2016-01-08 | 2022-04-27 | Kyoto University | Diagnostic method and medicine comprising adamts13 as main ingredient |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102121939A (zh) * | 2004-11-08 | 2011-07-13 | 三菱化学美迪恩斯株式会社 | 血小板血栓或脏器损伤的检测方法 |
CN102435166B (zh) * | 2011-09-30 | 2013-06-05 | 中国人民解放军第三军医大学第三附属医院 | 人体脏器模型力学损伤评估方法 |
CN104285148B (zh) * | 2012-05-07 | 2016-10-12 | 美迪恩斯生命科技株式会社 | 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029242A1 (ja) * | 2002-09-25 | 2004-04-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系 |
JP2004261067A (ja) * | 2003-02-28 | 2004-09-24 | Keio Gijuku | フォンビルブランド因子切断酵素機能の検出方法 |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
EP1568782A1 (de) * | 2004-02-25 | 2005-08-31 | Clemens Bockmeyer | Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE239501T1 (de) * | 1995-06-07 | 2003-05-15 | Chiron Corp | Regulierung der neutrophil elastase synthese und freisetzung |
US7763430B2 (en) * | 2003-04-22 | 2010-07-27 | Baxter International Inc. | Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies |
CN102121939A (zh) * | 2004-11-08 | 2011-07-13 | 三菱化学美迪恩斯株式会社 | 血小板血栓或脏器损伤的检测方法 |
WO2007094394A1 (ja) * | 2006-02-16 | 2007-08-23 | Mitsubishi Kagaku Iatron, Inc. | 意識障害患者における病態の検出方法及び検出用キット |
-
2005
- 2005-11-08 CN CN201010550130.4A patent/CN102121939A/zh active Pending
- 2005-11-08 CN CN200580037843.8A patent/CN101056989A/zh active Pending
- 2005-11-08 CA CA002586848A patent/CA2586848A1/en not_active Abandoned
- 2005-11-08 ES ES11151385T patent/ES2399607T3/es active Active
- 2005-11-08 EP EP05803016A patent/EP1816211A4/en not_active Withdrawn
- 2005-11-08 JP JP2006542468A patent/JP4875495B2/ja active Active
- 2005-11-08 US US11/718,853 patent/US7923255B2/en not_active Expired - Fee Related
- 2005-11-08 WO PCT/JP2005/020451 patent/WO2006049300A1/ja active Application Filing
- 2005-11-08 EP EP11151385A patent/EP2322646B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029242A1 (ja) * | 2002-09-25 | 2004-04-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系 |
JP2004261067A (ja) * | 2003-02-28 | 2004-09-24 | Keio Gijuku | フォンビルブランド因子切断酵素機能の検出方法 |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
EP1568782A1 (de) * | 2004-02-25 | 2005-08-31 | Clemens Bockmeyer | Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen |
Non-Patent Citations (8)
Title |
---|
CARDIOVASC SURG, vol. 10, no. 5, October 2002 (2002-10-01), pages 470 - 475 * |
CRAWLEY J.T. ET AL: "Proteolytic inactivation of ADAMTS13 by thrombin and plasmin", BLOOD, vol. 105, no. 3, 1 February 2005 (2005-02-01), pages 1085 - 1093, XP002995015 * |
DATABASE BIOSIS [online] GANDO S. ET AL: "Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase", XP002995016, Database accession no. (PREV199698604197) * |
DATABASE MEDLINE OTHENBURGER M. ET AL: "Leukocyte activation and phagocytotic activity in cardiac surgery and infection", XP002995017 * |
GANDO S. ET AL: "Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome", THROMB HAEMOST, vol. 75, no. 2, February 1996 (1996-02-01), pages 224 - 228, XP002995013 * |
J TRAUMA, vol. 39, no. 4, October 1995 (1995-10-01), pages 660 - 664 * |
MOORE J.C. ET AL: "Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders", BLOOD, vol. 98, no. 6, 15 September 2001 (2001-09-15), pages 1842 - 1846, XP002995012 * |
SAITO T. ET AL: "Microscopic polyangiitis associated with marked systemic bleeding tendency caused by disseminated intravascular coagulation", INTERN MED, vol. 42, no. 9, September 2003 (2003-09-01), pages 850 - 855, XP002995014 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007088849A1 (ja) | 2006-01-31 | 2007-08-09 | Mitsubishi Kagaku Iatron, Inc. | 播種性血管内凝固症候群の病態把握方法 |
AU2007210643B2 (en) * | 2006-01-31 | 2013-09-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for determination of condition of disseminated intravascular coagulation syndrome |
US8759018B2 (en) | 2006-01-31 | 2014-06-24 | Mitsubishi Chemical Medience Corporation | Method for determining treatment of disseminated intravascular coagulation |
WO2007094394A1 (ja) | 2006-02-16 | 2007-08-23 | Mitsubishi Kagaku Iatron, Inc. | 意識障害患者における病態の検出方法及び検出用キット |
US9297815B2 (en) | 2006-02-16 | 2016-03-29 | Lsi Medience Corporation | Method and kit for detecting condition in patient with disturbance of consciousness |
JP2008061622A (ja) * | 2006-09-11 | 2008-03-21 | Mitsubishi Kagaku Iatron Inc | 造血幹細胞移植療法の施行患者の病態把握方法 |
JP2008216137A (ja) * | 2007-03-06 | 2008-09-18 | Mitsubishi Kagaku Iatron Inc | 糖尿病性腎症患者の病態把握方法 |
EP3988938A1 (en) | 2016-01-08 | 2022-04-27 | Kyoto University | Diagnostic method and medicine comprising adamts13 as main ingredient |
US11567080B2 (en) | 2016-01-08 | 2023-01-31 | Kyoto University | Diagnostic agent and medicine comprising ADAMTS13 as main ingredient |
Also Published As
Publication number | Publication date |
---|---|
EP2322646B1 (en) | 2013-01-16 |
ES2399607T3 (es) | 2013-04-02 |
CN102121939A (zh) | 2011-07-13 |
CN101056989A (zh) | 2007-10-17 |
EP2322646A8 (en) | 2012-05-16 |
US20080096221A1 (en) | 2008-04-24 |
EP1816211A4 (en) | 2008-11-12 |
US7923255B2 (en) | 2011-04-12 |
EP2322646A1 (en) | 2011-05-18 |
JP4875495B2 (ja) | 2012-02-15 |
EP1816211A1 (en) | 2007-08-08 |
JPWO2006049300A1 (ja) | 2008-05-29 |
CA2586848A1 (en) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iba et al. | Potential diagnostic markers for disseminated intravascular coagulation of sepsis | |
Wildhagen et al. | Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients | |
JP4875495B2 (ja) | 血小板血栓症又は臓器障害の検出方法 | |
US6429017B1 (en) | Method for predicting the presence of haemostatic dysfunction in a patient sample | |
JP4486260B2 (ja) | 患者サンプルにおける止血機能不全の存在を予測するための方法および装置 | |
Onishi et al. | A pathological clarification of sepsis-associated disseminated intravascular coagulation based on comprehensive coagulation and fibrinolysis function | |
KR100788177B1 (ko) | 단백질 용액으로부터 인자 ⅶ을 활성화하는 프로테아제의활성을 측정하기 위한 방법 | |
US20090220990A1 (en) | Method and kit for detecting condition in patient with disturbance of consciousness | |
US8759018B2 (en) | Method for determining treatment of disseminated intravascular coagulation | |
Kroneman et al. | Monoclonal antibody-based plasma assays for fibrin (ogen) and derivatives, and their clinical relevance | |
Angstwurm et al. | D-dimer as marker for microcirculatory failure: correlation with LOD and APACHE II scores | |
Zhang et al. | Risk stratification and prognostic evaluation of endothelial cell‑specific molecule1, von Willebrand factor, and a disintegrin‑like and metalloprotease with thrombospondin type 1 motif for sepsis in the emergency department: An observational study | |
Larsen et al. | Inter-α-inhibitor heavy chain H4 and sepsis-related coagulation disturbances: Another link between innate immunity and coagulation | |
Becher et al. | Characterization of circulating thrombin in patients with septic shock: a prospective observational study | |
US20040101924A1 (en) | Proteolytic enzymes in urine as diagnostic parameters in diseases involving matrix remodelling | |
US8101366B2 (en) | Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent | |
Diaz et al. | The value of polymorphonuclear elastase in adult respiratory distress syndrome | |
JP2003107088A (ja) | 播種性血管内凝固症候群及びその発症前段階を検出する方法 | |
Sivula | Disseminated intravascular coagulation in critically ill patients | |
Adcock | Laboratory Evaluation of the Fibrinolytic System | |
KR20150124237A (ko) | 단백질 z의 혈액 항응고기능 분석방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2586848 Country of ref document: CA Ref document number: 2006542468 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11718853 Country of ref document: US Ref document number: 200580037843.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005803016 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005803016 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11718853 Country of ref document: US |